

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-2. (Canceled)

3. (Currently amended) A method for ~~preventing~~ treating or reducing the onset of symptoms of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental, or treating or reducing the severity of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental in a patient, comprising administering intratracheally or intrabronchially to a patient in need thereof an effective amount of (1) a pulmonary surfactant and (2) ~~a PDE5 inhibitor~~ SILDENAFIL or a pharmaceutically acceptable salt thereof.
4. (Currently amended) The method according to claim 3, wherein an effective amount of (1) a pulmonary surfactant and (2) ~~a PDE5 inhibitor~~ SILDENAFIL or a pharmaceutically acceptable salt thereof is administered simultaneously to a patient in need thereof.

5. (Currently amended) The method according to claim 3, wherein an effective amount of (1) a pulmonary surfactant and (2) ~~a PDE5 inhibitor~~ SILDENAFIL or a pharmaceutically acceptable salt thereof are administered in succession, close in time or remote in time, in any order whatever to a patient in need thereof.
6. (Canceled)
7. (Previously presented) The method according to claim 3, wherein the pulmonary surfactant is selected from the group consisting of Poractant alfa, Beractant, Bovactant, Colfosceril Palmitate, Surfactant-TA, Calfactant, Pumactant, Lusupultide and Sinapultide.
8. (Previously presented) The method according to claim 7, wherein the pulmonary surfactant is LUSUPULTIDE.
- 9-14. (Canceled)
15. (Previously presented) The method according to claim 3, wherein the disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental is selected from the group consisting of COPD, bronchitis, bronchial asthma, pulmonary fibroses, emphysema, interstitial pulmonary

disorders, pneumonia, ALI, ARDS, IRDS and asthma bronchiale.

16-48. (Canceled)